STOCK TITAN

TriSalus (TLSI) CCO reports 543-share tax-withholding sale, retains over 125K shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

TriSalus Life Sciences, Inc. Chief Commercial Officer Richard Marshak reported a sale of 543 shares of common stock at $2.67 per share. According to the footnote, these shares were sold solely to satisfy tax withholding obligations from the vesting of previously granted restricted stock units and do not represent a discretionary sale. After this transaction, Marshak directly holds 125,101 shares of common stock.

Positive

  • None.

Negative

  • None.
Insider Marshak Richard
Role Chief Commercial Officer
Sold 543 shs ($1K)
Type Security Shares Price Value
Sale Common Stock 543 $2.67 $1K
Holdings After Transaction: Common Stock — 125,101 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Shares sold 543 shares Non-derivative common stock sold on 2026-05-15
Sale price $2.67 per share Price for the 543 shares sold
Shares after transaction 125,101 shares Direct holdings following the reported sale
Net share change -543 shares Net-sell direction per transaction summary
restricted stock units financial
"in connection with the vesting of restricted stock units previously granted"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax withholding obligations financial
"shares sold to satisfy tax withholding obligations in connection with the vesting"
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
non-derivative financial
"transaction_type: non-derivative"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Marshak Richard

(Last)(First)(Middle)
6272 W. 91ST AVENUE

(Street)
WESTMINSTER COLORADO 80031

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Commercial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/15/2026S543(1)D$2.67125,101D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. This transaction does not represent a discretionary sale by the Reporting Person.
Remarks:
/s/ Mary Szela, Attorney-in-Fact05/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did TriSalus Life Sciences (TLSI) report for Richard Marshak?

TriSalus Life Sciences reported that Chief Commercial Officer Richard Marshak had 543 shares of common stock sold. The shares were sold in connection with tax withholding on the vesting of restricted stock units, rather than as a discretionary open-market sale.

How many TriSalus Life Sciences (TLSI) shares were involved and at what price?

The transaction covered 543 shares of TriSalus Life Sciences common stock at a price of $2.67 per share. This small block was sold to cover tax withholding obligations tied to vested restricted stock units previously granted to the executive.

Was the TLSI share sale by Richard Marshak a discretionary open-market trade?

No, the filing states the sale was to satisfy tax withholding obligations from vesting restricted stock units. It explicitly notes that the transaction does not represent a discretionary sale by Richard Marshak, indicating it was a routine, compensation-related event.

How many TriSalus Life Sciences (TLSI) shares does Richard Marshak hold after this transaction?

Following the tax-related sale, Richard Marshak directly holds 125,101 shares of TriSalus Life Sciences common stock. This shows the reported 543 shares represent only a small portion of his overall direct equity position in the company.

What is the nature of the security in Richard Marshak’s TLSI Form 4 filing?

The Form 4 transaction involves non-derivative common stock of TriSalus Life Sciences. The shares were linked to the vesting of previously granted restricted stock units, with a portion sold to cover associated tax withholding obligations for the executive.